Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...
In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.
Stereotactic arrhythmia radioablation reduces sustained ventricular tachycardia episodes and defibrillator shocks in patients with treatment-refractory disease, without treatment related deaths.
Medical Device Network on MSN
Adagio Medical reports positive six-month results in FULCRUM-VT trial
The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.
Adagio Medical Holdings, Inc. ADGM shares are up during Monday’s premarket session following the announcement of positive ...
Freedom From Shock and 59% Freedom From VT Recurrence in FULCRUM-VT Pivotal IDE Trial Meet Safety and Effectiveness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results